SCHEMBL3773280

SCHEMBL3773280

CC(C)(C)OC(=O)N[C@H](CCC(=O)O)C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSK P43235 9/20 0.48
CTSS P25774 6/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
HTT P42858 1/20 0.47
CTSL P07711 1/20 0.44
CTSB P07858 1/20 0.44
FOLH1 Q04609 3/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
RIMKLA Q8IXN7 1/20 0.42
NAALAD2 Q9Y3Q0 1/20 0.42
MEN1 O00255 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL863895 1.00 CTSK (0.48) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL863894 1.00 CTSK (0.48) CTSKCTSSCYP1A2CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL18261684 0.94 CTSK (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL2306568 0.92 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL10606035 0.92 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL2398972 0.92 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL6409351 0.92 CTSK (0.47) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL21685690 0.92 FOLH1 (0.42) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL21685691 0.92 FOLH1 (0.42) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL9196011 0.90 CTSK (0.50) CTSKCTSSCTSLCTSBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528803-A Deoxypyridinol artificial hapten as well as preparation method and application thereof 杭州博岳生物技术有限公司 2025-02-28 CN claimed
CN-118063718-A Nanometer medicine for inducing mitochondrial exocytosis and preparation method and application thereof 四川大学华西医院 2024-05-24 CN claimed
US-20250352662-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS INC (US) 2025-11-20 US disclosed
US-12440576-B2 Antibody drug conjugates comprising sting agonists MERSANA THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
EP-4622966-A1 NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-10-01 EP disclosed
EP-4598928-A1 FOLLICLE-STIMULATING HORMONE RECEPTOR (FSHR) TARGETED THERAPEUTICS AND USES THEREOF Radionetics Oncology, Inc. (US) 2025-08-13 EP disclosed
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis IDORSIA PHARMACEUTICALS LTD (CH) 2025-07-01 US disclosed
CN-119528803-A Deoxypyridinol artificial hapten as well as preparation method and application thereof 杭州博岳生物技术有限公司 2025-02-28 CN disclosed
US-12156870-B2 Antibody drug conjugates comprising sting agonists MERSANA THERAPEUTICS, INC. (US) 2024-12-03 US disclosed
CN-113412271-B Having cysteine residues Hamiltelin derivatives of (C) 住友制药株式会社 2024-10-22 CN disclosed
CN-118725014-A Mitochondrial targeting peptides 隐形生物治疗公司 2024-10-01 CN disclosed
US-20200190101-A1 Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2020-06-18 US disclosed
WO-2019118878-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS CORP. (MC) 2019-06-20 WO disclosed
CN-109517039-A Peptide compound, application thereof and composition containing peptide compound 凯惠科技发展(上海)有限公司 2019-03-26 CN disclosed
WO-2019031614-A1 ANTIBODY-DRUG CONJUGATES INCLUDING HEMIASTERLIN DERIVATIVE 大日本住友製薬株式会社 2019-02-14 WO disclosed
EP-3378495-A1 COMPOSITION COMPRISING NOVEL GLUTAMIC ACID DERIVATIVE AND BLOCK COPOLYMER, AND USE THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2018-09-26 EP disclosed
US-9636409-B2 Enzyme and receptor modulation using covalent conjugates of alpha,alpha-disubstituted glycine esters GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-05-02 US disclosed
US-20160151509-A1 ENZYME AND RECEPTOR MODULATION GLAXOSMITHKLINE IP DEV LTD (GB) 2016-06-02 US disclosed
US-20140088159-A1 ENZYME AND RECEPTOR MODULATION CHROMA THERAPEUTICS LTD. (GB) 2014-03-27 US disclosed
US-20100317865-A1 ENZYME AND RECEPTOR MODULATION c/o Chroma Therapeutics Ltd. (GB) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12156870-B2 Antibody drug conjugates comprising sting agonists STING1, CGAS, IFNAR1 CTSK 1976/4885CTSS 2082/4885CYP1A2 3483/4885
US-20140088159-A1 ENZYME AND RECEPTOR MODULATION CES1, GLRB, GLRA1 CTSK 736/4885CTSS 503/4885CYP1A2 841/4885
US-12440576-B2 Antibody drug conjugates comprising sting agonists STING1, CGAS, IFNAR1 CTSK 1976/4885CTSS 2082/4885CYP1A2 3483/4885
US-12344597-B2 Alkoxy-substituted pyridinyl derivatives as LPA1 receptor antagonists and their use in the treatment of fibrosis LPAR1, LPAR3, LPAR2 CTSK 2480/4885CTSS 2460/4885CYP1A2 899/4885
US-20200190101-A1 Composition Containing Novel Glutamic Acid Derivative And Block Copolymer, And Use Thereof GGCT, GGT1, TGM2 CTSK 3869/4885CTSS 3506/4885CYP1A2 3215/4885
US-20160151509-A1 ENZYME AND RECEPTOR MODULATION CES1, GLRB, GLRA1 CTSK 736/4885CTSS 503/4885CYP1A2 841/4885
US-20250352662-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS STING1, CGAS, IFNAR1 CTSK 1976/4885CTSS 2082/4885CYP1A2 3483/4885
US-20100317865-A1 ENZYME AND RECEPTOR MODULATION CES1, GLRB, GLRA1 CTSK 736/4885CTSS 503/4885CYP1A2 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.